INVESTORS

Share this on:
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz

What is this?

Investors

Corporate Profile

Genomic Health, Inc. (NASDAQ: GHDX) is a global cancer company focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.

GHDX Investor Fact Sheet (Q3 2011 / PDF)

Recent Press Releases

February 3, 2012
Genomic Health Presents Results Furthering Understanding of Biology of Prostate Cancer at the 2012 Genitourinary Cancers Symposium
January 30, 2012
Genomic Health to Announce Fourth Quarter and Year-End 2011 Financial Results and Host Conference Call on Monday, February 6, 2012
All Press Releases

Webcasts & Presentations

Genomic Health Fourth Quarter and Year-End 2011 Financial Results Webcast
February 6, 2012 - 1:30 PM PT
30th Annual J.P. Morgan Healthcare Conference
January 9, 2012 - 9:30 AM PT
Genomic Health Corporate Presentation
January 9, 2012
All Events & Webcasts

DISCLAIMER

The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.